Prostate cancer is a unique disease that is characterised at advanced stages by a dominance of bone-forming metastases. Our understanding of bone metastasis with support from experimental findings has led investigators to target these metastases therapeutically, and the report by Matthew Smith and colleagues
1 in
The Lancet is a result of these efforts.
Denosumab is an inhibitor of RANK ligand (RANKL), which is mechanistically implicated in, and clinically associated with, prostate cancer progression ...
Source: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61540-7/fulltext?rss=yes
wiccan pumpkin carvings mcrib pumpkin seeds mark herzlich malawi malawi
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.